Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma

Ispire Technology Inc. has announced a strategic joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. to manufacture and commercialize nicotine pouch products. The deal, which involves an undisclosed amount, marks Ispire's entry into the rapidly expanding oral nicotine market. The announcement was made on May 12, 2026, positioning Ispire to leverage its global platform alongside Jincheng Pharma's pharmaceutical-grade manufacturing capabilities.

Ispire Technology, listed on NASDAQ under the ticker ISPR, is known for its innovative approaches in vaping technology and precision dosing. The company aims to diversify its product offerings beyond vaping hardware, tapping into the growing demand for nicotine pouches. According to market research from Grand View Research, the nicotine pouch sector was valued at approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion. This joint venture is expected to accelerate Ispire's entry into this lucrative market segment.

Jincheng Pharmaceutical, listed on the Shenzhen Stock Exchange, is a diversified global pharmaceutical company with around 3,800 employees and over 30 affiliated companies. Its expertise encompasses the research, development, and production of pharmaceutical intermediates and active pharmaceutical ingredients. In this joint venture, Jincheng Pharma will contribute essential manufacturing equipment and technical expertise, which will facilitate a rapid operational ramp-up and support near-term production and commercialization of nicotine pouch products.

The collaboration is designed to leverage Ispire's strengths in precision dosing and regulatory compliance, combined with Jincheng's manufacturing excellence. This strategic alignment aims to differentiate their nicotine pouch offerings in an increasingly competitive marketplace. The joint venture is expected to utilize existing commercial relationships to support initial production, while also exploring additional business development opportunities within the oral nicotine segment.

The formation of this joint venture reflects broader trends in the nicotine market, where consumer preferences are shifting towards reduced-risk products. As regulatory frameworks evolve and public health initiatives continue to shape market dynamics, companies like Ispire and Jincheng Pharma are well-positioned to capitalize on the growing demand for innovative nicotine delivery systems. The successful execution of this joint venture could not only enhance Ispire's revenue streams but also contribute to the overall growth and diversification of the nicotine products sector.